Live Price Coverage: Trillium Therapeutics Inc. Can’t Be More Risky. Trades Sigfnicicantly Lower

Live Price Coverage: Trillium Therapeutics Inc. Can't Be More Risky. Trades Sigfnicicantly Lower

The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) is a huge mover today! About 2.56M shares traded hands or 3035.10% up from the average. Trillium Therapeutics Inc. (NASDAQ:TRIL) has risen 49.90% since April 1, 2016 and is uptrending. It has outperformed by 48.68% the S&P500.
The move comes after 6 months negative chart setup for the $114.14 million company. It was reported on Nov, 3 by We have $5.98 PT which if reached, will make NASDAQ:TRIL worth $13.70M less.

Analysts await Trillium Therapeutics Inc. (NASDAQ:TRIL) to report earnings on November, 8. They expect $-0.83 earnings per share, down 418.75% or $0.67 from last year’s $-0.16 per share. After $-0.75 actual earnings per share reported by Trillium Therapeutics Inc. for the previous quarter, Wall Street now forecasts 10.67% negative EPS growth.

According to Zacks Investment Research, “Trillium Therapeutics Inc. is an immuno-oncology company. It engages in developing therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRP?Fc and a CD200 monoclonal antibody, which target two key immunoregulatory spathway that tumor cells exploit to evade the host immune system. Trillium Therapeutics Inc. is based in Canada.”

More important recent Trillium Therapeutics Inc. (NASDAQ:TRIL) news were published by: which released: “Trillium Therapeutics Inc.” on August 24, 2009, also published article titled: “Trillium Therapeutics Inc. (TRIL): Finding The Next Blockbuster Biotech Stock”, published: “Trillium Therapeutics Inc Clinical Trial Review, Market Size, Segment, and …” on November 01, 2016. More interesting news about Trillium Therapeutics Inc. (NASDAQ:TRIL) was released by: and their article: “News Trillium Therapeutics Inc.TRIL” with publication date: December 20, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment